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Abstract
Background: Metformin is the first-line oral therapy for type 2 diabetes mellitus.
However, its mode of action is poorly defined. There is an increasing awareness
regarding the cross talk of gut microbiota and metformin. The current review aimed to
assess the bidirectional relationship between metformin and gut microbiota.
Methods: Electronic search was conducted in Pub Med and the first 100 articles in
Google Scholar published until November 2019. However, only randomized controlled
trials on humans published in the English language were included. The terms “gut
microbiota,” “gut flora ”and “ metformin” were as keywords to perform the search.
Although 124 articles were retrieved, only six met the inclusion criteria of the study.
Results: Of the six full texts of randomized controlled trials included in the study,
two-thirds were published in Europe, one in the USA, and one in China. Six hundred-
thirty five patients were included and the duration of the studies ranged from seven
days to six months. The studies concluded that microbiota modulates some metformin
actions on plasma glucose; while metformin enhances the abundance of microbiota
that positively affect insulin resistance and plasma glucose.
Conclusion: The current review showed that microbiota dysbiosis may mediate
metformin antidiabetic effects. Whereas metformin shifted the gut microbiota toward
the beneficial species ameliorating insulin resistance. The present study might provide
insights into a novel therapeutic approach to treat type 2 diabetes mellitus.
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1. Introduction
Over decades of clinical use as the first-line drug for the treatment of diabetes mellitus,
metformin has proved to be safe and well tolerated. Metformin enhances insulin action
in the liver and skeletal muscles to decrease insulin production and increase non-
oxidative disposal of glucose. When taken together, these actions reduce insulin in the
hyperglycemic state with little potential for hypoglycemia [1]. However, the mechanism
of action of metformin is not completely understood. There is an increasing awareness
about the role of the gastrointestinal tract in the regulation of plasma glucose, mainly
through microbiota effects on incretins, bile acids, and glucagon-like peptide [2].
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The inhibition of the mitochondrial respiratory chain mediated by activation of adeno-
sine monophosphate-activated protein kinase (AMPK) thought as the center of met-
formin action has been challenged and it may account for indirect changes in insulin
sensitivity [3]; blocking this pathway is not followed by loss of metformin effects on
glucose. In addition, oral metformin is more effective than intravenous, raising the
possibility of an important gut role.
The gut microbiota is the first protection system of the gastrointestinal tract; it is
composed of thousands of species and more than 15,000 kinds of bacteria in weight
equal to 1 kg [4]. Recent studies showed that the gut microbiota might play an important
role in the pharmacodynamics and pharmacokinetics of metformin, while the drug
metformin alters the functional capacity of gut microbiota [5, 6]. The gut microbiota
is an area of extensive research due to its associations with various diseases including
diabetes mellitus. An interesting recent study conducted among patients with type
2 diabetes mellitus (50%), overweight/obesity (78%), co-morbid psychiatric (65%), and
opioid use (45%) disorders in the USA concluded the interaction between metformin,
gut microbiota, and opioid use [7].
The current review assessed the role of metformin on the gut microbiota, and whether
the gut microbiota mediates the actions of metformin.
2. Methods
An electronic search was conducted in Pub Med database and the first 100 articles
in Google Scholar for relevant articles in the English language; the search was limited
to randomized controlled trial on humans from the first published article to November
2019. The terms “gut flora” “metformin,” and “gut microbiota were used as keywords
with protean and/or OR. Articles published in languages other than English and studies
on animals were not included. One hundred twenty-four articles were retrieved. The
titles and abstracts of the articles were screened for the removal of duplications and
irrelevant articles. Only six articles fulfilled the inclusion criteria. Figure 1 illustrates the
different phases of the search process.
3. Results
The six selected randomized controlled trials (four from Europe, one from the USA,
and one from Asia) included 635 patients who received metformin for a duration
ranging from seven days to six months, the dose ranged from 1 gr/day to 1.7 gr/day.
All studies showed that metformin altered microbiota and improved glucose tolerance.
In addition, metformin increased the gut microbiota species with positive effects on
insulin resistance and plasma glucose, some studies reported a favorable effect on
lipids as well (Table 1).
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Figure 1: Flow diagram of the different phases of the systematic review (PRISMA flowchart).
4. Discussion
In the present review of randomized controlled studies, Napolitano et al. [8] assessed
14 patients on metformin 1000 mg/day and followed them up for three months. The
study assessed gut microbiota, gut hormones including glucagon-like peptide-1 (GLP-1),
peptide tyrosine-tyrosine, glucose-dependent insulinotropic peptide), and blood and
fecal bile acids at four points (baseline, after metformin withdrawal, when the fasting
plasma glucose was 25% above normal, and after the drugs were reintroduced. The
researcher observed an increased level of GLP-1 and reduction in bile acids with
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TABLE 1: The relationship between metformin and gut microbiota.
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metformin, while the reverse happened with metformin withdrawal. Furthermore, the
researchers observed that the abundance of Bacteroidetes was negatively correlated
with changes in cholic acid and conjugates, while phylum Firmicutes abundance was
positively correlated. These results imply that metformin exerts gut-based pharmacol-
ogy. A study published in the United States [9] found that the addition of microbiome
modulator to metformin increased both efficacy and tolerability in the form of glucose
profile improvement and lesser gastrointestinal manifestations (the most common side
effects of metformin). The aforementioned findings supported the previous observations
regarding the role of gut microbiota on metformin. Also, it may pave the way for more
use of this essential first-line antidiabetic medication. Pendersen et al. [10] assessed
the effects of prebiotics on gut microbiota and found no positive results. However,
the authors proposed that metformin might play a role. A study [11] with a long period
of follow-up (120 days) observed that microbiota mediates some metformin antidia-
betic effects; moreover, fecal transplantation from metformin-treated patients improved
glycemia among mice. This observation suggested that metformin may play a major
role in fecal transplantation, and supporting the previous finding, fecal transplantation
was an effective measure including diabetes mellitus, autism, and inflammatory bowel
disease among various diseases [12–14]. It is interesting to note that metformin had an
immediate effect on the gut microbiota starting from the first 24 hr [15], a study with
a relatively large sample size [16] showed that metformin shifted the gut microbiota,
ameliorated hyperlipidemia, and improved glycemic control.
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5. Conclusion
The current review showed that microbiota dysbiosis might mediate the antidiabetic
effects of metformin. While metformin shifted the gut microbiota toward the beneficial
species, the current review showed that gut microbiota might serve as a promising
target for diabetes control, which has become a worldwide public health threat.
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